Understanding bladder cancer biology to find new biomarkers and therapies
Official title: Project 1 Dissecting the key Xenobiotic alterations by transcriptomics, epigenetic and metabolomic profiling in Urothelial Carcinoma
Funded at Tuskegee University · NIH-11621784 · Data updated 2026-11-12
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tuskegee University NIH-funded |
| Lab location | 1 site (Tuskegee Institute, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $300,853 |
| NIH project number | 4UH3HG013553-02 |
| Project ID | NIH-11621784 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with high-grade bladder cancer (BLCA) who have or may benefit from biomarker-driven approaches.
✕Less likely to help
Patients with non-bladder cancers or very early-stage disease not targeted by biomarker-driven strategies may not benefit.
What this research studies
Researchers will profile gene activity, epigenetic marks, and metabolism in bladder cancer tissues to understand what drives aggressive tumors. The project builds on findings about aldehyde oxidase 1 and how its loss may rewire metabolism to support cancer growth. By integrating transcriptomics, epigenetics, and metabolomics, the study aims to identify biomarkers and pathways that could be targeted by future therapies. This work could pave the way for more precise diagnostics and new treatment approaches for patients with high-grade bladder cancer.
Why it matters
Potential benefit: If successful, the findings could lead to better biomarkers and new targets for therapies that slow progression and reduce recurrence.
How similar studies have gone: Previous work suggests metabolic and epigenetic changes can influence bladder cancer behavior, supporting the potential for meaningful advances here.
Where this research is happening
-
Tuskegee University
Tuskegee Institute, United States Active
Researchers
- Principal investigator: Bedi, Deepa — Tuskegee University
- Study coordinator: Bedi, Deepa
Related research
Other NIH-funded projects on the same topics.
-
Improved 3D guidance for kidney-sparing endoscopic UTUC treatment
A Vanderbilt team is testing a new 3D-guided approach to precisely locate and treat upper tract urothelial cancer during kidney-sparing endoscopic procedures.
-
Immune cells in bladder cancer: predicting who benefits from stronger pre-surgery therapy
This grant aims to find immune clues in muscle-invasive bladder cancer to identify which patients will best respond to intensified pre-surgery treatment.
-
Synergistic immune boost for bladder cancer with EphrinB2 blocker and PD-1 therapy
A phase II trial tests whether a new EphrinB2 blocker (sEphB4-HSA) plus pembrolizumab can help patients with muscle-invasive bladder cancer who have EphrinB2 and low Nectin4 to fight their cancer.
-
HER2 PET scans to find HER2 differences and predict response to HER2-targeted therapy in bladder cancer
This project uses a PET scan that lights up HER2 to help show which people with metastatic bladder (urothelial) cancer might benefit from HER2-targeted antibody-drug conjugates.
-
Treating bladder cancer with ARID1A gene changes
This project will develop new treatment approaches for people with bladder cancer whose tumors have changes in the ARID1A gene.
-
IL-12 bladder immune therapy for dogs with invasive bladder cancer
This project gives a sticky IL-12 immune medicine directly into the bladder of pet dogs with invasive bladder cancer to shrink tumors and stimulate immune responses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.